Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

被引：109

作者：

Eker, Barbara

Ortmann, Johannes ^{[2
]}

Migliori, Giovanni B. ^{[3
]}

Sotgiu, Giovanni ^{[4
]}

Muetterlein, Ralf ^{[5
]}

Centis, Rosella ^{[3
]}

Hoffmann, Harald ^{[6
]}

Kirsten, Detlef ^{[7
]}

Schaberg, Tom ^{[8
]}

Ruesch-Gerdes, Sabine

Lange, Christoph ^{[1
]}

机构：

[1] Res Ctr Borstel, Div Clin Infect Dis, D-23845 Borstel, Germany

[2] Karl Hansen Clin, Bad Lippspringe, Germany

[3] World Hlth Org, Collaborating Ctr TB & Lung Dis, Tradate, Italy

[4] Univ Sassari, I-07100 Sassari, Italy

[5] Reg Hosp, Pasberg, Germany

[6] Asklepios Hosp, Gauting, Germany

[7] Hosp Grosshansdorf, Grosshansdorf, Germany

[8] Deakoness Hosp, Rotenburg, Germany

来源：

EMERGING INFECTIOUS DISEASES | 2008年 / 14卷 / 11期

关键词：

D O I：

10.3201/eid1411.080729

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany in 2004-2006. In 177 (4%) of 4,557 culture-positive TB cases, Mycobacterium tuberculosis isolates were identified as MDR TB, an additional 7 (0.15%) met criteria for XDR TB. Of these 184 patients, 148 (80%) were born in countries of the former Soviet Union. In patients with XDR TB, hospitalization was longer (mean +/- SD 202 +/- 130 vs. 123 +/- 81 days; p = 0.015) and resistance to all first-line drugs was more frequent (36% vs. 86%; p = 0.013) than in patients with MDR TB. Seventy-four (40%) of these 184 patients received treatment with linezolid. Treatment success rates ranged from 59% for the entire cohort (59% for MDR TB and 57% for XDR TB) to 87% for those with a definitive outcome (n = 125; 89% for MDR TB and 80% for XDR TB). Extensive drug susceptibility testing and availability of second- and third-line drugs under inpatient management conditions permit relatively high treatment success rates in MDR and XDR TB.

引用

页码：1700 / 1706

页数：7

共 39 条

[11] Linezolid for the treatment of multidrug-resistant tuberculosis [J].